bioRxivCancer Biology
Locally-invasive, castrate-resistant prostate cancer in a Pten/Trp53 double knockout mouse model of prostate cancer monitored with non-invasive bioluminescent imaging
C. Yong, D. Moose, N. Bannick, M. Vanneste, R. Svensson, P. Breheny, J. Brown, M. Cohen, M. Henry
Abstract
Here we have improved an existing mouse model of prostate cancer based on prostate-specific deletion of Pten and Trp53 by incorporating a Cre-activatable luciferase reporter. By coupling the deletion of those genes to the activation of a luciferase reporter, we were able to monitor tumor burden non-invasively over time. We show that, consistent with previous reports, deletion of both Pten and Trp53 on a C57BL/6 background accelerates tumor growth and results in both the loss of androgen receptor expression and castrate resistant tumors as compared with loss of Pten alone. Loss of Trp53 results in the development of sarcomatoid histology and the expression of markers of epithelial-to-mesenchymal transition Zeb1 and vimentin, with kinetics and penetrance dependent on whether one or both alleles of Trp53 were deleted. Homozygous deletion of Trp53 and Pten resulted in uniformly lethal disease by 25 weeks. While we were able to detect locally invasive disease in the peritoneal cavity in aggressive tumors from the double knockout mice, we were unable to detect lymphatic or hematogenous metastatic disease in lymph nodes or at distant sites.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis
K. K. Chaudagar, H. Hieromnimon, … A. Patnaik·bioRxiv·May 23, 2023
- Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss
Jessica Kalla, Thomas Dillinger, … Gerda Egger·Cell Reports MethodsPeer-reviewed·Mar 30, 2026
- CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality
Jean Ching-Yi Tien, Jie Luo, … Arul M. Chinnaiyan·Cell Reports MedicinePeer-reviewed·Oct 1, 2024
- Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos
Andrew Hartley, Laura C.A. Galbraith, … Imran Ahmad·British Journal of CancerPeer-reviewed·Jan 30, 2025
- Loss of PI5P4Kalpha slows the progression of a Pten mutant basal cell model of prostate cancer
Joanna Triscott, Marika Lehner, … Mark A. Rubin·Molecular Cancer ResearchPeer-reviewed·Oct 9, 2024
- Loss of PIK3CA allows in vitro growth but not in vivo progression of KRAS mutant lung adenocarcinoma in a syngeneic orthotopic implantation model
Abigail Booth, Giuseppe Caso, … Harold Bien·CellsPeer-reviewed·Mar 12, 2026